CR20180368A - Compuestos de dihidroquinolinsulfonamida de alquilo - Google Patents
Compuestos de dihidroquinolinsulfonamida de alquiloInfo
- Publication number
- CR20180368A CR20180368A CR20180368A CR20180368A CR20180368A CR 20180368 A CR20180368 A CR 20180368A CR 20180368 A CR20180368 A CR 20180368A CR 20180368 A CR20180368 A CR 20180368A CR 20180368 A CR20180368 A CR 20180368A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- dihydroquinolinsulfonamide
- renting
- present
- sodium channels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona compuestos de Fórmula I, y sales farmacéuticamente aceptables de estos, que son inhibidores de los canales de sodio activados por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen compuestos de la presente invención
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269518P | 2015-12-18 | 2015-12-18 | |
PCT/US2016/067617 WO2017106871A1 (en) | 2015-12-18 | 2016-12-19 | Alkyl dihydroquinoline sulfonamide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20180368A true CR20180368A (es) | 2018-09-28 |
Family
ID=57758767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180368A CR20180368A (es) | 2015-12-18 | 2016-12-19 | Compuestos de dihidroquinolinsulfonamida de alquilo |
Country Status (23)
Country | Link |
---|---|
US (2) | US10383866B2 (es) |
EP (1) | EP3390392B1 (es) |
JP (1) | JP6903663B2 (es) |
KR (1) | KR20180094946A (es) |
CN (1) | CN108602804A (es) |
AU (1) | AU2016369652B2 (es) |
CA (1) | CA3008484C (es) |
CL (1) | CL2018001631A1 (es) |
CO (1) | CO2018007436A2 (es) |
CR (1) | CR20180368A (es) |
EA (1) | EA038286B1 (es) |
IL (1) | IL259918B (es) |
MA (1) | MA44065A (es) |
MX (1) | MX2018007432A (es) |
MY (1) | MY197595A (es) |
NZ (1) | NZ743377A (es) |
PE (1) | PE20181328A1 (es) |
PH (1) | PH12018501285A1 (es) |
SG (1) | SG11201805066RA (es) |
TN (1) | TN2018000214A1 (es) |
UA (1) | UA122913C2 (es) |
WO (1) | WO2017106871A1 (es) |
ZA (1) | ZA201804033B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
MX2022015857A (es) | 2020-06-10 | 2023-01-24 | Amgen Inc | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. |
JP2021195368A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2013025883A1 (en) * | 2011-08-17 | 2013-02-21 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
EP2788332A1 (en) * | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
US9212182B2 (en) * | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-12-19 CN CN201680074274.2A patent/CN108602804A/zh active Pending
- 2016-12-19 TN TNP/2018/000214A patent/TN2018000214A1/en unknown
- 2016-12-19 CA CA3008484A patent/CA3008484C/en active Active
- 2016-12-19 US US16/062,606 patent/US10383866B2/en active Active
- 2016-12-19 MX MX2018007432A patent/MX2018007432A/es active IP Right Grant
- 2016-12-19 KR KR1020187019086A patent/KR20180094946A/ko not_active Application Discontinuation
- 2016-12-19 EA EA201891319A patent/EA038286B1/ru unknown
- 2016-12-19 MY MYPI2018000912A patent/MY197595A/en unknown
- 2016-12-19 SG SG11201805066RA patent/SG11201805066RA/en unknown
- 2016-12-19 NZ NZ743377A patent/NZ743377A/en unknown
- 2016-12-19 MA MA044065A patent/MA44065A/fr unknown
- 2016-12-19 WO PCT/US2016/067617 patent/WO2017106871A1/en active Application Filing
- 2016-12-19 UA UAA201806895A patent/UA122913C2/uk unknown
- 2016-12-19 PE PE2018001136A patent/PE20181328A1/es unknown
- 2016-12-19 EP EP16823447.4A patent/EP3390392B1/en active Active
- 2016-12-19 CR CR20180368A patent/CR20180368A/es unknown
- 2016-12-19 JP JP2018531483A patent/JP6903663B2/ja active Active
- 2016-12-19 AU AU2016369652A patent/AU2016369652B2/en active Active
-
2018
- 2018-06-10 IL IL259918A patent/IL259918B/en active IP Right Grant
- 2018-06-14 PH PH12018501285A patent/PH12018501285A1/en unknown
- 2018-06-15 ZA ZA2018/04033A patent/ZA201804033B/en unknown
- 2018-06-15 CL CL2018001631A patent/CL2018001631A1/es unknown
- 2018-07-17 CO CONC2018/0007436A patent/CO2018007436A2/es unknown
-
2019
- 2019-07-12 US US16/510,816 patent/US20200009129A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA201804033B (en) | 2019-04-24 |
MX2018007432A (es) | 2018-09-21 |
AU2016369652A1 (en) | 2018-06-28 |
EP3390392A1 (en) | 2018-10-24 |
EP3390392B1 (en) | 2021-10-06 |
CL2018001631A1 (es) | 2018-09-28 |
CA3008484C (en) | 2023-10-17 |
EA038286B1 (ru) | 2021-08-04 |
WO2017106871A1 (en) | 2017-06-22 |
US10383866B2 (en) | 2019-08-20 |
IL259918A (en) | 2018-07-31 |
US20180369227A1 (en) | 2018-12-27 |
TN2018000214A1 (en) | 2019-10-04 |
KR20180094946A (ko) | 2018-08-24 |
CA3008484A1 (en) | 2017-06-22 |
BR112018012298A2 (pt) | 2018-12-04 |
UA122913C2 (uk) | 2021-01-20 |
NZ743377A (en) | 2022-05-27 |
CO2018007436A2 (es) | 2018-07-19 |
PE20181328A1 (es) | 2018-08-20 |
MY197595A (en) | 2023-06-27 |
IL259918B (en) | 2020-06-30 |
JP2019504016A (ja) | 2019-02-14 |
EA201891319A1 (ru) | 2018-11-30 |
JP6903663B2 (ja) | 2021-07-14 |
PH12018501285A1 (en) | 2019-02-04 |
SG11201805066RA (en) | 2018-07-30 |
CN108602804A (zh) | 2018-09-28 |
MA44065A (fr) | 2021-05-26 |
US20200009129A1 (en) | 2020-01-09 |
AU2016369652B2 (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
CO2018011064A2 (es) | Inhibidores de bromodominios | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
SV2016005311A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
DOP2018000150A (es) | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje | |
CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
CL2017002957A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
CL2021000282A1 (es) | Inhibidores de ckd8/19 |